2023
Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study
Hoppe B, Castellino S, Pei Q, Charpentier A, Keller F, Vega R, Roberts K, Parikh R, Punnett A, Parsons S, McCarten K, Flampouri S, Kessel S, Wu Y, Cho S, Kelly K, Hodgson D. Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s62-s63. DOI: 10.1016/j.ijrobp.2023.06.362.Peer-Reviewed Original ResearchProgression-free survivalBrentuximab vedotinABVE-PCIrradiated patientsMediastinal adenopathyRadiotherapy utilizationContemporary trialsRT modalityOpen-label phase 3 studyExcellent progression-free survivalUse of PTProgression-free survival ratesProton therapyHodgkin's lymphoma studyUtilization of RTSevere acute toxicityPhase 3 studyPediatric Hodgkin lymphomaSimilar acute toxicityAcute toxicityMATERIAL/METHODSDifferent RT modalitiesEligible patientsMedian followPediatric patients
2021
Pediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL management